Frank G. Rucker

Heinz Galinski Str. 1
Berlin, BE 13347, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Prognostic Impact of COVID-19 Inflammation Score Response: A Sub-Group Analysis on Critically Ill Patients of the RuxCoFlam Trial.

Prognostic Impact of COVID-19 Inflammation Score Response: A Sub-Group Analysis on Critically Ill Patients of the RuxCoFlam Trial.

Journal: Life (Basel, Switzerland)
Published: April 05, 2025

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.

Journal: Blood advances
Published: May 24, 2024

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).

Journal: HemaSphere
Published: April 12, 2024

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology.

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology.

Journal: Blood advances
Published: June 05, 2023

TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.

TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.

Journal: British journal of haematology
Published: November 25, 2021

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.

Journal: Leukemia
Published: May 21, 2021

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements.

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements.

Journal: Haematologica
Published: November 16, 2020

A call for HoLEP: en-bloc vs. two-lobe vs. three-lobe.

A call for HoLEP: en-bloc vs. two-lobe vs. three-lobe.

Journal: World journal of urology
Published: October 01, 2020

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.

Journal: Blood advances
Published: June 15, 2020

Rescue of Non-Informative Circulating Tumor DNA to Monitor the Mutational Landscape in NSCLC.

Rescue of Non-Informative Circulating Tumor DNA to Monitor the Mutational Landscape in NSCLC.

Journal: Cancers
Published: June 11, 2020

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.

Journal: Blood
Published: June 11, 2020

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.

Journal: Blood
Published: April 06, 2020
Showing 1-12 of 36

Last Updated: 09/26/2026